Consequently, ARRB2 can inhibit lung cancer progression regulated by two signaling axes, TRAF6-TAB2 signaling axis for NF-κB activation and the TRAF6-BECN1 signaling axis for autophagy induction, in response to TLR3 and TLR4 stimulation. Here, NFKB1 is linked to lung cancer.